1. Introduction {#sec1}
===============

Chemotherapy has long been used to treat all types of cancer. Although survival benefits from adjuvant systemic chemotherapy in breast cancer have been thoroughly documented \[[@B1]\], success is not uniform with many still dying after the initial chemotherapy. The unpredictable tumor response to chemotherapy in any given patient and the significant toxicity manifested in all demand a better strategy for delivering cancer therapy.

In selective subtypes of breast cancer, therapies targeting specific signal transduction and/or metabolic pathways have been successful. For example, Herceptin for HER2/neu positive breast cancer \[[@B2], [@B3]\] and poly(ADP ribose) polymerase (PARP) inhibitors for triple-negative breast cancer with defective DNA-repair \[[@B4], [@B5]\] are among the recent successes of targeted therapy. The success of target therapy has led to an explosion of interest in developing tailored systemic therapy.

Breast cancer is a heterogeneous disease molecularly, histologically, and clinically. Clinical outcomes from the same treatment vary widely even among patients with tumors of identical stage and histology. Breast cancers developed from an accumulation of genetic alterations may partially explain the differences observed including tumor responses to anticancer agents \[[@B6]\]. Recently gene expression analysis has identified five subtypes of breast cancer which overlaps with clinical tumor classification according to the expression of three biomarkers, estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2). Clinically these three markers are prognostically and therapeutically important in guiding treatment selection \[[@B7]--[@B10]\]; however, they do not fully reflect the complexity and heterogeneity of breast cancer and do not always predict the outcome of the treatment. For example, Herceptin as a single agent or in combination with chemotherapy has been shown to reduce recurrent disease and to save lives in patients with HER2-positive breast cancer, yet a significant number of HER2 overexpression tumors do not respond to the treatment \[[@B11]\]. Additional molecular targets are expected to improve tailored treatment in the future.

Proteomics has been employed in recent years to identify new disease-related biomarkers for cancer diagnosis and implementation of tailored treatment \[[@B12]--[@B15]\]. The tumor proteomes representing a global protein expression of cancer may provide new insights into the molecules that govern the dynamic cellular activities of tumor cells. Therefore, we choose to study breast tumor protein signatures in breast cancer classification and in predicting tumor response to treatment.

Previously we used SELDI mass spectrometry to profile tumor response to neoadjuvant treatment and found that significant m/z profile differences existed between cancers of nonresponders (tumor regression rate ≤25%) and others (tumor regression rate \>25%) \[[@B16]\]. In this current study we have applied the LC-MS/MS technology to study the breast cancer proteomes in human tissues and identify unique proteins that may have the potential to separate two subtypes of breast cancer (TNBC versus HER2+) and to predict drug responses within each subtype.

2. Materials and Methods {#sec2}
========================

2.1. Collection of Breast Tumor Tissues and Classification of Response {#sec2.1}
----------------------------------------------------------------------

Breast tumors were collected, processed, and banked as previously described \[[@B16]\]. This study was approved by the UCLA institutional review board (IRB). Tumors from 39 consented patients with locally advanced breast cancer were collected from a neoadjuvant clinical trial \[[@B17]\]. Eleven were triple-negative breast tumors (TNBC, ER-/PR-/HER2-), and 28 were HER2-positive tumors (HER2+). The tumor specimens were uniformly collected according to a standard operating procedure established in our laboratory. Baseline tumor specimens were obtained by either core needle biopsy or surgical biopsy before starting the neoadjuvant Taxotere/Carboplatin/±Herceptin treatment (TC ± H). Evaluation of tumor response to the treatment was measured both by pathologic examination of surgically removed tissue and by clinical assessment including physical examination and/or imaging studies. The pathological response of the tumor was reported as either pathologically complete response (pCR) or having residual tumor. Because a baseline tumor size by pathologic evaluation was not possible in patients receiving neoadjuvant treatment, the clinically or imaging-measured tumor size prior to chemotherapy was used as the baseline tumor size. Pathological assessment after chemotherapy including tumor size, lymph node staging, and tumor biomarkers was performed on the specimen obtained from the definitive breast cancer surgery \[[@B16]\]. The tumor regression rate (TRR) was used to evaluate tumor response induced by neoadjuvant therapy, and it was calculated as follows: (baseline tumor size − residual tumor size)/baseline tumor size × 100%, where the baseline tumor size was measured clinically, and the postchemotherapy residual invasive tumor size was measured pathologically. The tumor response was categorized into three groups: responders (TRR \> 75%, R), intermediate responders (25% \< TRR ≤ 75%, IR), and nonresponders (TRR ≤ 25%, NR).

2.2. Protein Extraction and Abundant Protein Depletion {#sec2.2}
------------------------------------------------------

Protein extraction from tumors and depletion of abundant proteins from tumor lysates were performed as previously described \[[@B16]\]. Briefly, frozen tumors were homogenized in liquid nitrogen and suspended in 1% Triton X-100. The samples were refrozen at −80°C and thawed on ice twice. Following centrifugation (10,000 g, 10 min, 4°C), the supernatants were subjected to albumin and immunoglobulin depletion using an albumin and IgG removal kit (Amersham) as well as hemoglobin depletion using Ni-NTA magnetic agarose beads (Qiagen). Protein concentrations of each preparation were determined by the BioRad protein assays.

Because the blood proteins in the breast cancer tissue can cause significant ion suppression of lower abundance cancer-related proteins/peptides which may mask ion signals of less abundant peptides with similar M/Z ratios and retention times. In addition, the over presentation of serum proteins in the specimen may lower the amount of the cancer-related proteins available for LC-MS/MS analysis \[[@B18]\]. As a result, selected abundant serum proteins were depleted from the tissue extracts. Our preliminary test has shown more than 95% albumin, IgG and hemoglobin were removed by the described method, and more meaningful proteins have been detected.

2.3. Trypsin Digestion {#sec2.3}
----------------------

The dried protein samples were dissolved in 6 M guanidine HCl, reduced with DTT (5 mM--15 mM), and alkylated using 10 mM iodoacetamide. Samples were then diluted with NH~4~HCO~3~ to lower guanidine HCl concentration (1 M), mixed with trypsin (1 : 50 w/w ratio, sequencing grade, Promega) containing 50 mM ammonium bicarbonate, and incubated at 37°C overnight. Samples were desalted by C18 Microspin columns (The Nest Group), and the eluates were dried in a vacuum centrifuge.

2.4. LC-MS/MS Analysis {#sec2.4}
----------------------

Each digested and dried sample was prepared for LC-MS/MS analysis as previously reported \[[@B19]\]. Briefly the samples were redissolved in Buffer A (H~2~O/acetonitrile/formic acid, 98.9/1/0.1, typically at 0.7 *μ*g protein/uL), and aliquots were injected (5 *μ*L) onto an in-house-prepared C18 trap. The retained materials were placed onto a reverse phase column (New Objective C18, 15 cm, 75 *μ*M diameter, 5 *μ*m particle size equilibrated in Buffer A) and eluted (300 nL/min, Eksigent Nanolc-2D) with an increasing concentration of Buffer B (acetonitrile/water/formic acid, 98.9/1/0.1; min/%B: 0/5, 10/10, 112/40, 130/60, 135/90, 140/90). Eluted peptides were analyzed by MS and data-dependent MS/MS (collision-induced dissociation) using online data-dependent tandem mass spectrometry (LTQ Orbitrap, Thermo Fisher Scientific) in which the seven most abundant precursor ions were selected for MS/MS. Before testing the experimental specimens, the reproducibility of LC-MS/MS analysis was confirmed by examining the triplicates of two different tissue samples, and similar proteins were identified from the triplicates of each sample with more than 90% overlapping.

2.5. Database Searching and Analysis {#sec2.5}
------------------------------------

BioWorks software (version 3.3.1, Thermo Fisher Sceintific), based on the SEQUEST algorithm (SRF v.5, Thermo Fisher Scientific), was used to search the mass spectra against a human trypsin indexed database (human.fasta.hdr database, Version 12.2, 227246 entries) as described by Whelan et al. \[[@B19]\]. SEQUEST was searched with a fragment ion mass tolerance of 1.00 Da and a parent ion tolerance of 50 PPM. The search tolerated up to two missed trypsin cleavages with variable modifications for carboxyamidomethylation (57.02146 Da) and methionine oxidation (15.99492 Da). Scaffold (version 3.0.3, Proteome Software, Inc.) was used to validate MS/MS-based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than 95.0% probability as specified by the Peptide Prophet Algorithm \[[@B20]\]. Protein identifications were accepted if they could be established with a greater than 99.0% probability and contained at least 2 identified peptides. Protein probabilities were assigned by the Protein Prophet Algorithm \[[@B21]\].

From the resulting MS/MS protein identifications, a list of proteins was generated for each sample. A list of semi-quantitative protein abundances in the different samples was developed using the normalized spectrum counts of the identified tryptic peptides from each protein, as compiled by the Scaffold program. The protein lists and their relative abundances were then compared to find differentially expressed proteins between two groups.

2.6. Statistic Analysis {#sec2.6}
-----------------------

The data files exported from Scaffold were further processed as Excel files. The top 60% (180) abundant proteins of the 315 identified proteins were further selected for hierarchical clustering and supervised classification studies. Those proteins with at least a 2-fold difference in mean spectral counts between any two groups were selected for analysis in the web-based Gene Expression Profile Analysis Suite (GEPAS, version 4.0, <http://www.gepas.org>). Five different classification algorithms were tested to select candidate markers in the GEPAS software: Support Vector Machines (SVM), K-Nearest Neighbor Clustering (KNN), Diagonal Linear Discriminant Analysis (DLDA), Prediction Analysis with Microarrays (PAM), and Self-Organizing Map (SOM).

2.7. Immunohistochemistry Staining {#sec2.7}
----------------------------------

A small portion of each of the baseline tumors was embedded in OCT and stored at −80°C. Endogenous peroxidase activity was quenched with 0.6% hydrogen peroxide in methanol for 10 minutes, and endogenous biotin was eliminated by Biotin Blocking System (DAKO, x0590). After blocking with 1 : 5 diluted normal goat serum or fetal bovine serum, slides were incubated for 1 hour with primary antibody (CK19, mouse IgG, ready to use, DAKO; galectin-3-binding protein, Goat IgG, 1 : 200 dilution, R&D) and 30 minutes with biotinylated secondary antibody (biotinylated anti-mouse Ig, 1 : 800 dilution, DAKO; biotinylated anti-goat Ig, 1 : 200 dilution, Vector Labs). Antigen-antibody complexes were then detected by the StreptABComplex/HRP method (DAKO) using diaminobenzidine as a chromogenic substrate (DAKO). Immunostained slides were lightly counterstained with hematoxylin. For negative controls, primary antibodies were replaced by mouse IgG or goat IgG.

3. Results {#sec3}
==========

3.1. Patient Characteristics {#sec3.1}
----------------------------

The reported thirty-nine baseline tumor specimens included 28 HER2-positive breast cancers and 11 TNBC with HER2 status determined by fluorescence in situ hybridization (FISH) assay. Fifteen of the 28 HER2+ patients were randomized to receive TC, and the remaining 13 received TC and Herceptin (TCH) before surgery. All eleven patients with TNBC received neoadjuvant TC. Following the neoadjuvant treatment, 28 patients with HER2+ tumors showed 12 responders (R), including 7 with pathological complete response (pCR) and 5 with a tumor regression rate \>75%, 12 intermediate responders (IR), and 4 nonresponders (NR). In the TNBC group, there were 7 responders including 6 pCR and 1 with tumor regression rate \>75%, 3 IR, and 1 NR. The clinical characteristics and pathologic features of the 11 TNBC and 28 HER2+ cases are summarized in Tables [1](#tab1){ref-type="table"}(a) and [1](#tab1){ref-type="table"}(b).

3.2. Protein Comparison between HER2+ and TNBC Groups {#sec3.2}
-----------------------------------------------------

Proteins identified by MS/MS from the 39 tumors showed that 48 proteins were only found in HER2+ tumors, 24 were only seen in TNBC, and 243 proteins were shared by both, but the quantity of the shared proteins differed widely in the two tumor types. In this study, we focused the analysis on the top 60% abundant proteins (180/315) detected in the 39 tumors.

The 20 most abundant shared proteins by both subtypes of cancer were summarized in [Table 2](#tab2){ref-type="table"}. Among them apolipoprotein A-I and D, enolase 1, tumor rejection antigen (gp96) 1, transgelin 2, cofilin 1, profilin, heat shock proteins 70, and annexins 5 were found to be present in significant quantity in both types of breast cancer. Some of these shared proteins found in sufficient amount may be useful for breast cancer detection.

Of the 180 top abundant proteins observed in the 39 breast cancer specimens, 61 were found to have a ≥2-fold difference of spectrum counts between the two subtypes of breast cancer (HER2+ versus TNBC). Because some of these proteins were not detected in every sample, we further refined the list of differential proteins by selecting only those detected in ≥50% of the cases in either group. The selected 44 differentially expressed proteins were tested by hierarchical clustering to classify HER2+ breast cancer versus TNBC. These differentially expressed proteins correctly classified all 28 HER2+ tumors and 8 of the 11 TNBC by unweighted pair-group method using arithmetic average (UPGMA) ([Figure 1](#fig1){ref-type="fig"}).

Self-validation of selected proteins in tumor classification was tested using a supervised classification. The 44 differentially expressed proteins were used to build a model separating subtypes of the tumors by Prophet, a web interface from the Gene Expression Profile Analysis Suite. Error rates were calculated as the number of misclassified tumors divided by total tumor cases tested. The error rates using various numbers of proteins by different models (SVM, KNN, DLDA, PAM, and SOM) were estimated by leaving-one-out tests (see File A in Supplementary Material available online at doi:10.1155/2011/896476). SVM had the lowest error rate (10%, 4/39) with 90% accuracy in tumor classification. The top 20 protein candidates ([Table 3](#tab3){ref-type="table"}) selected by SVM model successfully classified all 28 HER2+ tumors and 7 of the 11 TNBC. Among the 20 differentially expressed proteins, G3BP, ALDH1A1, and complement component 1 inhibitor overexpression were found to be associated with TNBC subtype, whereas overexpression of CK19, transferrin, transketolase, and thymosin *β*4 and *β*10 were associated with HER2+ tumors ([Figure 2](#fig2){ref-type="fig"}).

3.3. Proteins Correlated with Different Tumor Response to Neoadjuvant Treatment among HER2+ Tumors {#sec3.3}
--------------------------------------------------------------------------------------------------

Of the 28 HER2+ tumors, there were 12 R (including 7 with pCR), 12 IR, and 4 NR. We compared proteomic differences between the two groups with extreme tumor response (pCR and NR) and found that 48 of the 180 proteins had an expressional difference ≥2-fold between 7 pCR versus 4 NR tumors. Self-validation of these potential marker proteins by five supervised classification methods suggested that the KNN had the lowest error rate (9%, 1/11) in predicting tumor response (Files B and C). By using KNN = 1 method, 100% (4/4) NR and 85.7% (6/7) pCR were correctly grouped by 20 selected proteins ([Table 4](#tab4){ref-type="table"}). Of the 20 proteins, overexpressions of enolase1, vimentin, and L-plastin in HER2-positive tumors were associated with pCR, whereas high level of heat shock proteins 70 (Hsp70) and peroxiredoxin 5 (Prx V) were found only in the NR cases.

3.4. Proteins Predicting TNBC Tumor Response to Neoadjuvant Treatment {#sec3.4}
---------------------------------------------------------------------

Among the 11 TNBC cases, there were 7 R (including 6 pCR), 3 IR, and 1 NR. Due to the small sample size, the proteins of responders\' tumor (R) were compared to all the remaining tumors with less response (IR + NR). Sixty-three of 180 proteins had a ≥2-fold mean differences between the two groups of TNBC with different response to the same treatment. Self-validation of these proteins by five supervised classification methods was used to compare the accuracy in predicting a tumor response. Using DLDA method, 6 of 7 tumors in the R group and 3 of 4 tumors in IR/NR group were correctly classified by the 30 selected proteins (error rate 18%) (Files D and E). Of these 30 proteins, the increased heat shock 70 kDa protein 8, periostin, Ras homolog gene family member A (RhoA), actinin alpha 4, cathepsin D preproprotein, annexin 1, and several other proteins were associated with drug resistance in TNBC ([Table 5](#tab5){ref-type="table"}).

3.5. Evaluation of CK19 and G3BP Expression in TNBC and HER2+ Frozen Tumors {#sec3.5}
---------------------------------------------------------------------------

CK19 and G3BP protein expressions were tested in breast cancer tumors by immunohistochemistry. The CK19 and G3BP staining showed cytoplasmic/membrane staining pattern in breast cancer cells. The overexpression of CK19 was found in HER2+ breast tumors ([Figure 3](#fig3){ref-type="fig"}) while the expression of G3BP was found to be upregulated in most TNBC ([Figure 4](#fig4){ref-type="fig"}). The concordance findings between the mass spectrometry analysis and immunohistochemical staining of the same tumor suggested that high-throughput mass spectrometry may be used as a screening tool to discover disease-related biomarkers.

4. Discussion {#sec4}
=============

In this discovery study, the MS-detected proteomic differences between two subtypes of breast cancer (HER2+ versus TNBC tumors) were explored, and proteomic prediction of tumor response to neoadjuvant chemotherapy was investigated. LC-MS/MS data sets of proteins from the 39 tumors analyzed allowed us to identify several candidate proteins that could classify tumor subtypes and predict tumor response to neoadjuvant chemotherapy.

Two clinical subtypes of breast cancer, HER2-positive and triple-negative breast cancers, defined by immunohistochemical staining and fluorescence in situ hybridization of three biomarkers of breast cancer have also been confirmed by gene analysis as two distinctive types of breast cancer. In this study, we reported that proteomic analysis could also separate the two subtypes by the unique biosignature associated with each type of breast cancer ([Table 3](#tab3){ref-type="table"}). We also reported the potential of proteomic analysis in classifying drug-resistant TNBC and HER2+ breast cancer (Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"}).

Through an extensive literature review, some of the identified proteins have reported roles that are relevant to cancer biology and treatment. In TNBC tumors, we observed that the levels of G3BP, ALDH1A1, and complement component 1 inhibitor protein were preferentially elevated. All of them have been reported to have important biological properties in cancer progression. G3BP, also known as 90-kDa Mac-2-binding protein, is a member of the beta-galactoside-binding protein family and has a role in modulating cell-cell and cell-matrix interactions. It has been shown that G3BP is overexpressed in a variety of cancer cells such as colon, gastric, and breast cancer, and its overexpression appears to correlate with tumor progression, and metastasis \[[@B22]--[@B26]\]. Our report is the first to describe G3BP overexpression in human TNBC by both mass spectrometry analysis and immunohistochemical staining method.

One protein correlated with triple-negative breast cancer meriting a discussion is ALDH1A1, a detoxifying enzyme responsible for oxidizing intracellular aldehydes. This process is important in early differentiation of stem cells through conversion of retinol to retinoic acid \[[@B27]\]. ALDH1 is considered to be a breast cancer stem cell marker and also a predictor for poor prognosis \[[@B27]\]. Because breast cancer stem cells have been implicated in radiation and chemotherapy resistance, as well as increasing the potential for metastasis, our finding of ALDH1A1 in TNBC may explain the more frequent relapse in TNBC patients. Previously, we have observed an overexpression of ALDH1 in TNBC when compared with hormone-receptor-positive and HER2-negative breast cancer \[[@B28]\]. In this paper, we also found a preferential overexpression of ALDH1 in TNBC over HER2-positive tumors. The unique overexpression of ALDH1 in TNBC tumors may point out an important population as the origin of some TNBC whereby notch signaling-dependent stem cell targets may be leveraged for target therapy development \[[@B29]\].

A different set of proteins was found preferentially elevated in HER2+ tumors. This list included CK19, transferrin, transketolase, and thymosin *β*4 and *β*10, and the biological significance of some of them will be discussed.

Cytokeratins are known to be important in cellular motility, signaling, and division. While CK8/CK18 were similarly detected in both HER2+ and TNBC tumors, elevated CK19 was more commonly found in HER2+ tumors. Our observation coincides with the finding reported by Schulz et al. using a combination of 2D-DIGE/mass spectrometry and western blot \[[@B30]\]. Both our current and previous papers suggest that CK19 is low in TNBC when compared with either HER2-positive or HER2-negative but hormone-receptor-positive breast cancer \[[@B31]\]. Although the biological significance and the mechanism of reduced CK19 in TNBC are not clear, it could be related to the frequent recurrence and poor overall survival rate seen in TNBC patients \[[@B32]\].

Transferrin, another protein associated with HER2-positive cancer, is essential for cell growth and iron-dependent metabolic activities including DNA synthesis, electron transport, and mitogenic signaling pathways \[[@B33]\]. The elevation of transferrin receptor (CD71) was reported to be a marker of poor outcome \[[@B33]\]. Vyhlidal et al. reported that transferrin is regulated by estrogen hormone \[[@B34]\], and tamoxifen was shown to be ineffective in ER-positive breast cancer with transferrin overexpression which coincides with the tamoxifen resistance observed in HER2-positive hormone-receptor-positive breast cancer. Taken together, the ineffectiveness of tamoxifen in women with HER2-positive and hormone-receptor-positive cancer may be related to the prevalent expression of transferrin in these tumors.

Thymosin *β*4 and *β*10 are members of a family of highly conserved small acid peptides that control the growth and differentiation of many cell types. They act as major actin-sequestering factor and play a role in cancer cell motility, invasion and metastasis \[[@B35], [@B36]\]. Thymosin *β*4 stimulates tumor metastasis by activating cell migration and angiogenesis in lung cancer and is associated with poor prognosis \[[@B37]--[@B39]\]. Elevations of thymosin *β*4 and *β*10 have also been reported in a number of other cancers including melanoma and breast cancer \[[@B40]\]. In the same tumor, the level of thymosin *β*10 was significantly higher in the cancer cells than in the normal breast parenchymal cells of the uninvolved area \[[@B41]\]. Its association with high-grade and poorly differentiated cancer cells is consistent with our findings of thymosin *β*10 overexpression in HER2-positive breast cancer. Further studies are required to confirm its overexpression and to determine its role in HER2-positive breast cancer.

In this study, we also reported the MS-identified protein signature predicting drug-induced tumor response in HER2-positive tumors. We found that enolase 1, vimentin, L-plastin, and ApoD predicted a favorable response of HER2-positive tumors. In contrast, elevated peroxiredoxin 5 and heat shock proteins 70 were found in nonresponding HER2-positive tumors.

Enolase 1(ENO1), a phosphopyruvate dehydratase, is a key glycolytic enzyme involved in anaerobic metabolism under hypoxic conditions of cancer growth, and a cell surface plasminogen receptor for tumor invasion. Overexpression of ENO1 in breast, and lung cancers is associated with tumor progression and rapid tumor growth \[[@B42]\]. While our study did not specifically studying the prognostic value of ENO1, the observation of ENO1 in HER2-positive tumors supports the prognostic importance of this molecule. While it was seen in the more aggressive subtype of breast cancer, our study showed ENO1 elevation in HER2-positive tumors seemed to indicate a better tumor response to chemotherapy.

Vimentin is a member of the intermediate filament family. Along with microtubules and actin microfilaments, vimentin is an integral component of the cell cytoskeleton. In cancer, altered vimentin level is associated with a dedifferentiated phenotype, increased motility, invasiveness, and poor clinical prognosis \[[@B43], [@B44]\]. Vimentin overexpression was found in 90.5% of grade III breast carcinomas \[[@B45]\] which may explain its presence in both HER2-positive breast cancer and in TNBC. Our study found that vimentin, although an aggressive marker for breast cancer growth, is another indicator for a favorable tumor response to chemotherapy. L-plastin is an actin-binding protein involved in cancer cell migration, invasion, and metastasis, and its expression in breast cancer cell lines correlates with the degree of invasiveness \[[@B30], [@B46]\]. In this paper, L-plastin overexpression in HER2-positive breast cancer was associated with a likelihood of pCR.

In contrast to those molecules associated with favorable tumor response to neoadjuvant therapy, high levels of Prx V in HER2-positive breast cancers were found to be associated with poor response to the same chemotherapy regimen. Peroxiredoxins (Prxs) represent a novel group of peroxidases containing high antioxidant activity involved in cell differentiation and apoptosis \[[@B47]\], and Prx V is particularly effective in reducing reactive oxygen species (ROS). Moreover, Prx V is found in peroxisomes and mitochondria where protection against ROS is mostly needed. The antioxidant activity of Prx V may be associated with drug resistance of the tumor cells.

While some molecules are unique to the characteristics of individual subtype of breast cancer, Hsp70 overexpression was found by us to be associated with drug resistance in both HER2-positive and TNBC tumors. Heat shock proteins are overexpressed in a wide range of human cancers and are implicated in tumor cell proliferation, differentiation, death, invasion, metastasis, and immune recognition \[[@B48]\]. Consistent with the cellular functions of Hsp70, clinically it has been correlated with poor prognosis in breast, endometrial, cervical, and bladder cancers. Others have also reported that Hsp70 mediated drug resistance through its inhibitory effect on chemotherapy-induced tumor cell apoptosis \[[@B48]--[@B50]\].

In TNBC tumors, a list of different proteins was found to be overexpressed in tumors resistant to neoadjuvant chemotherapy. In addition to Hsp70, proteins such as periostin precursor (OSF-2), RhoA, actinin *α*4, cathepsin D preproprotein, and annexin 1 predicted a poor response of TNBC to treatment. Although all of them were known to have important cancer biological properties, they have not been linked to chemotherapy susceptibility until now.

Periostin was originally identified in a mouse osteoblastic cell line as an extracellular matrix adhesion protein for pre-osteoblasts. In addition to forming bones, teeth, and heart, periostin was recently found to be overexpressed in various types of human cancer. Periostin interacts with multiple cell-surface receptors (most notable integrins) and signals via the PI3-K/Akt and other pathways to promote cancer cell survival, epithelial-mesenchymal transition, invasion, and metastasis \[[@B51]\]. In breast cancer, periostin was found upregulated at both the mRNA and protein levels \[[@B51]--[@B55]\]. Activation of the Akt/PKB cellular survival pathway with consequential protection of tumor cells and endothelial cells from stress-induced cell death \[[@B51], [@B56]\] may contribute to the periostin-mediated drug resistance in cancer. To our knowledge, this is the first paper to link periostin to drug resistance in TNBC.

RhoA is a member of the Ras superfamily. It is involved in the regulation and timing of cell division. It is a small GTPase protein known to regulate the actin cytoskeleton in the formation of stress fibers. RhoA protein levels were significantly increased in breast cancer compared with the matched normal tissue. It has been reported by Fritz et al. that an elevated RhoA protein level correlated with increasing breast tumor grade and poor prognosis \[[@B57]\].

Actinin *α*4 is another interesting protein that we found to indicate a poor tumor response to neoadjuvant therapy. It is thought that the actinin *α*4 cross-links actin filaments and connects the actin cytoskeleton to the cell membrane. The accumulation of actinin *α*4 in the cytoplasm is related to tumor invasiveness and metastasis, probably by enhancing cell motility, and was suggested to be a novel prognosticator in patients with ovarian and breast cancer \[[@B58]\].

Cathepsin D, an acid protease, is active in intracellular protein breakdown and is involved in the pathogenesis of several diseases. Its preproprotein secreted by cancer cells, acting as a mitogen on both cancer and stromal cells, stimulates both proinvasive and prometastatic properties of cancer cells. Many studies found that cathepsin D preproprotein/cathepsin D level represents an independent prognostic factor in a variety of cancers and is, therefore, considered to be a potential target for anticancer therapy \[[@B59]\]. Others have also shown that overexpression of cathepsin D in human breast cancers is associated with a higher risk of relapse and metastasis \[[@B59]--[@B61]\]. In our study, cathepsin D preproprotein appeared to be a drug-resistant marker in TNBC.

Although many proteins identified in this pilot study are interesting with promising potential, this study has several limitations. First, the tumors used in this study were collected from a clinical trial which provided many controlled clinical data; however, the sample size available for proteomic analysis was small. As a result, the findings derived from a small sample size always warrant a cautious interpretation. Second, the HER2-positive group consisted of tumors with different ER and PR status which might interfere with the conclusion. The potential false associations with HER2 might be solved by stratifying the HER2-positive tumors according to hormonal receptor status in a larger study. Lastly, the HER2-positive patients in this study were randomized to receive either chemotherapy alone or chemotherapy with Herceptin. The selected drug-resistant markers may represent the resistance not only to the chemotherapy but also to Herceptin.

In summary, our study has led to the identification of a list of important breast cancer proteins. The study also suggests that MS-based protein profiling may be an important tool in discovery of cancer biosignatures for tumor subtyping and prediction of treatment outcome. When sufficiently validated, some of these candidate protein markers could be used to improve breast cancer care. In addition, due to the heterogeneous and complex nature of the breast cancer tissue specimens, more refined methods need to be developed to maximize the protein identification to allow the capture of the best protein candidate markers for clinical use.

Supplementary Material {#supplementary-material-sec}
======================

###### 

The error rates of tumor classification predicted by different sets of proteins in each model (SVM, KNN, DLDA, PAM, and SOM) were estimated by leaving-one-out test (GEPAS, version 4.0, <http://www.gepas.org>).

File A: SVM had the lowest error rate (10%, 4/39) in tumor classification using 20 proteins listed in Table 3.

File B and C: KNN had the lowest error rate (9%, 1/11) in predicting HER2-positive tumor response using 20 proteins listed in Table 4. By using KNN = 1 method, 100% (4/4) tumors in NR and 85.7% (6/7) tumors in pCR were correctly grouped.

File D and E: DLDA had the lowest error rate (18%, 2/11) in predicting TNBC tumor response using 30 proteins listed in Table 5. 85.7% (6/7) tumors in the R group and 75% (3/4) tumors in IR/NR group were correctly classified.

###### 

Click here for additional data file.
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![Heat map displaying the expression of 44 proteins in 28 HER2-positive and 11 TNBC tumors. Classification of 39 breast cancer cases into 2 groups based on tumor subtypes (HER-positive tumors and TNBC tumors) by the hierarchical clustering using GEPAS software. Each column represents a case as labeled on top, the short labeling cases are "TNBC" with sample ID, and long labeling cases are "HER2-positive" with sample ID. Each row represents a protein ID as indicated at the right. 44 proteins were expressed by ≥2-fold differences and detected in ≥50% of the cases in either group.](IJPRO2011-896476.001){#fig1}
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Representative proteins differentially expressed by HER2+ and TNBC tumors. (a)--(c): proteins preferentially expressed in TNBC. (d)-(e): proteins preferentially expressed in HER2+ tumors.
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![CK19 expressions detected by LC-MS/MS and immunohistochemical (IHC) staining. Elevated CK19 expressions found in HER+ tumor group by LC-MS/MS and confirmed by IHC in most of the frozen HER2+ tumors. (a) Normalized spectrum count of CK19 detected in 39 breast cancer tissues. (b) Immunohistochemical staining of CK19 in a HER2+ frozen tumor (power 200x). (c) Immunohistochemical staining of CK19 in a TNBC frozen tumor (power 200x).](IJPRO2011-896476.003){#fig3}

![G3BP expressions detected by LC-MS/MS and immunohistochemical (IHC) staining. Elevated G3BP expressions found in TNBC group by LC-MS/MS and confirmed by IHC in most of the frozen TNBC tumors. (a) Normalized spectrum count of G3BP detected from 39 breast cancer tissues. (b) Immunohistochemical staining of G3BP in a TNBC frozen tumor (power 200x). (c) Immunohistochemical staining of G3BP in a HER2+ frozen tumor (power 200x).](IJPRO2011-896476.004){#fig4}

###### 

\(a\) Clinical characteristics of 11 TNBC tumors

  LTQ Orbitrap sample ID   Patient age   Ethnicity   TR %     Response   T stage   Histological type   ER   PR   FISH R/G ratio   Neoadjuvant
  ------------------------ ------------- ----------- -------- ---------- --------- ------------------- ---- ---- ---------------- -------------
  \#1                      61            White       80       R          T3        IDC                 −    −    1.10             TC
  \#2                      29            Hispanic    −60      NR         T3        IDC                 −    −    0.92             TC
  \#5                      55            Hispanic    100      R (pCR)    T3        IDC                 −    −    0.92             TC
  \#6                      54            Hispanic    100      R (pCR)    T3        IDC                 −    −    1.01             TC
  \#7                      40            Asian       45       IR         T3        IDC                 −    −    1.17             TC
  \#8                      44            White       100^a^   R (pCR)    T3        IDC                 −    −    1.00             TC
  \#9                      49            Hispanic    48       IR         T4        IDC                 −    −    1.10             TC
  \#10                     53            White       100      R (pCR)    T3        IDC                 −    −    1.20             TC
  \#11                     84            Asian       100      R (pCR)    T4        IDC                 −    −    1.03             TC
  \#36                     45            Hispanic    30       IR         T3        IDC                 −    −    1.27             TC
  \#37                     38            White       100      R (pCR)    T2        IDC                 −    −    1.10             TC

^a^LN positive without residual primary cancer.

###### 

\(b\) Clinical characteristics of 28 HER2+ tumors

  LTQ Orbitrap sample ID   Patient age   Ethnicity   TRR %    Response   T stage   Histological type   ER   PR   FISH R/G ratio   Neoadjuvant
  ------------------------ ------------- ----------- -------- ---------- --------- ------------------- ---- ---- ---------------- -------------
  \#17                     38            White       40       IR         T3        IDC                 \+   −    12.4             TC
  \#18                     63            Asian       100      R (pCR)    T3        IDC                 \+   −    12.7             TCH
  \#19                     57            White       100      R (pCR)    T3        IDC                 −    −    4.6              TC
  \#20                     56            Asian       78.2     R          T4        IDC                 \+   −    10.71            TC
  \#21                     51            Black       56       IR         T3        IDC                 −    −    19.97            TCH
  \#22                     31            White       45.5     IR         T3        IDC                 \+   \+   2.2              TC
  \#23                     55            White       80       R          T4        IDC                 \+   \+   3.8              TC
  \#24                     45            Asian       75       IR         T4        IDC                 \+   \+   2.7              TCH
  \#25                     42            Hispanic    63.5     IR         T4        IDC                 \+   −    2.5              TC
  \#26                     50            White       67.1     IR         T3        IDC                 −    −    2.41             TCH
  \#27                     33            White       82.9     R          T3        IDC                 \+   \+   3.03             TCH
  \#28                     40            White       66.7     IR         T3        IDC                 −    −    8.1              TC
  \#29                     35            Hispanic    100^a^   R (pCR)    T3        IDC                 −    −    42.2             TCH
  \#30                     44            White       97.3     R          T4        IDC                 −    −    4.2              TC
  \#31                     30            White       −7.7     NR         T3        IDC                 \+   −    5                TC
  \#32                     57            White       25%      NR         T4        IDC                 \+   −    \>4              TCH
  \#33                     37            White       33.3     IR         T2        IDC                 \+   \+   9.49             TC
  \#34                     36            Black       25       NR         T3        IDC                 −    −    5.1              TC
  \#35                     42            White       60       IR         T2        IDC                 \+   \+   4.5              TCH
  \#38                     55            White       42.3     IR         T4        IDC                 −    −    3.9              TCH
  \#39                     47            White       100^b^   R (pCR)    T3        IDC                 \+   \+   \>20             TCH
  \#40                     50            Asian       100^b^   R (pCR)    T3        IDC                 \+   \+   4.19             TCH
  \#41                     58            White       50       IR         T4        IDC                 \+   \+   2.1              TCH
  \#42                     40            Asian       60       IR         T2        IDC                 −    −    16               TC
  \#43                     37            White       −85.6    NR         T3        IDC                 \+   \+   3.1              TC
  \#44                     49            White       100^b^   R (pCR)    T2        IDC                 \+   −    7.7              TCH
  \#45                     55            Asian       92.6     R          T3        IDC                 −    −    9.9              TC
  \#46                     41            Hispanic    100      R (pCR)    T2        IDC                 −    −    9.2              TC

^a^LN positive and residual DCIS; ^b^residual DCIS only.

###### 

The 20 most abundant proteins shared by both HER2-positive and TNBC tumors.

  Identified proteins                                       Accession no.       MW
  --------------------------------------------------------- ------------------- --------
  Apolipoprotein A-I                                        gi∣90108664         28 kDa
  Vimentin                                                  gi∣62414289         54 kDa
  Enolase 1                                                 gi∣4503571          47 kDa
  Alpha-1 antitrypsin                                       gi∣157086955        45 kDa
  Triosephosphate isomerase 1                               gi∣4507645 (+2)     27 kDa
  Cyclophilin A                                             gi∣1633054          18 kDa
  Apolipoprotein D                                          gi∣619383           28 kDa
  Cofilin 1                                                 gi∣5031635          19 kDa
  Chaperonin                                                gi∣31542947         61 kDa
  Transgelin 2                                              gi∣4507357          22 kDa
  Heat shock 70 kDa protein 5                               gi∣16507237         72 kDa
  Tumor rejection antigen (gp96) 1                          gi∣4507677          92 kDa
  S100 calcium-binding protein A11                          gi∣5032057          12 kDa
  Lumican precursor                                         gi∣4505047          38 kDa
  Tropomyosin 4                                             gi∣4507651          29 kDa
  ATP synthase, H+ transporting, mitochondrial F1 complex   gi∣32189394         57 kDa
  Prosaposin isoform a preproprotein                        gi∣11386147         58 kDa
  Profilin                                                  gi∣157838211 (+4)   15 kDa
  Heat shock 70 kDa protein 8 isoform 1                     gi∣5729877          71 kDa
  Annexin 5                                                 gi∣4502107          36 kDa

###### 

Top 20 differentially expressed proteins selected by supervised classification methods for classifying two tumor subtypes.

  Rank   Accession no.      Protein name                                    MW        HER2+/TNBC mean   Subcellular location          Function
  ------ ------------------ ----------------------------------------------- --------- ----------------- ----------------------------- ---------------------------------------------------------------------------------------------------------
  1      gi∣10946578        Thymosin *β*4                                   5 kDa     2.99              Cytoplasm, cytoskeleton       For cytoskeletal binding, involved in cell growth and maintenance
  2      gi∣4507521         Transketolase                                   68 kDa    4.20              Cytosol                       Involved in metabolism. Associated with cell proliferation of uterine and cervical cancer.
  3      gi∣1633054         Cyclophilin A                                   18 kDa    2.45              Cytoplasma                    Involved in accelerate the folding of proteins
  4      gi∣73858568        Complement component 1 inhibitor                55 kDa    0.33              Secreted                      Regulating the complement cascade
  5      gi∣4557871         Transferrin                                     77 kDa    16.38             Secreted                      Essential for cell growth and iron-dependent metabolic processes
  6      gi∣90111766        Keratin type I cytoskeletal 19                  44 kDa    11.29             Cytoskeleton                  Involved in metastatic progression of breast cancer
  7      gi∣10863895        Thymosin *β*10                                  5 kDa     2.25              Cytoplasm, cytoskeleton       For cytoskeletal binding, involved in cell growth and maintenance
  8      gi∣5031863         Galectin-3-binding protein                      65 kDa    0.41              Secreted                      Modulating cell-cell and cell-matrix interactions
  9      gi∣4505753 (+1)    Phosphoglycerate mutase 1                       29 kDa    2.51              Cytosol                       Involved in glycolysis
  10     gi∣5174391         Aldo-keto reductase family 1, member A1         37 kDa    0.30              Cytosol                       Involved in the reduction of biogenic and xenobiotic aldehydes
  11     gi∣21361176        Aldehyde dehydrogenase 1A1                      55 kDa    0.39              Cytoplasm                     Detoxifying enzyme responsible for oxidating of intracellular aldehydes. A marker for cancer stem cells
  12     gi∣4505185         Macrophage migration inhibitory factor          12 kDa    0.36              Secreted, cytoplasm           Involved in integrin signaling pathways
  13     gi∣4507645 (+2)    Triosephosphate isomerase 1                     27 kDa    2.49              Cytosol, nucleus              Fatty acid biosynthesis, gluconeogenesis, glycolysis, lipid synthesis
  14     gi∣4930167         Aldolase A                                      39 kDa    6.41              Extracellular, cytoskeleton   Involved in glycolysis
  15     gi∣116241280       Adenylyl cyclase-associated protein 1 (CAP 1)   52 kDa    3.03              Membrane                      Regulating filament dynamics, cell polarity and signal transduction,
  16     gi∣21624607 (+5)   Coactosin-like 1                                16 kDa    0.42              Cytoplasm, cytoskeleton       Regulating the actin cytoskeleton
  17     gi∣160420317       Filamin A, alpha isoform 2                      281 kDa   3.10              Cytoplasm                     Anchoring transmembrane proteins to the actin cytoskeleton, scaffold for cytoplasmic signaling proteins
  18     gi∣6005942         Valosin-containing protein                      89 kDa    3.26              Cytosol, nucleus              Fragmentation of Golgi stacks during mitosis and reassembly
  19     gi∣5174539         Cytosolic malate dehydrogenase                  36 kDa    2.52              Cytoplasm                     Involved glycolysis, oxidation reduction, and tricarboxylic acid cycle
  20     gi∣33286418 (+2)   Pyruvate kinase 3                               58 kDa    6                 Cytoplasm, nucleus            Involved in glycolysis

###### 

Top 20 proteins predicting tumor response to neoadjuvant treatment in HER2-positive tumors.

  Rank   Protein name                                               Accession no.      pCR/NR mean   Subcellular location                   Function
  ------ ---------------------------------------------------------- ------------------ ------------- -------------------------------------- --------------------------------------------------------
  1      Enolase 1                                                  gi∣4503571         2.59          Cytoplasm, cell membrane               Multifunctional enzyme
  2      Heterogeneous nuclear ribonucleoprotein A2/B1 isoform B1   gi∣14043072        3.51          Nucleus, cytoplasm                     Pre-mRNA processing
  3      Heat shock 70 kDa protein 1                                gi∣75061728        0.24          Cytoplasm                              Stress response
  4      Vimentin                                                   gi∣62414289        9.94          Cytosol                                Class III intermediate filaments
  5      Vesicle amine transport protein 1                          gi∣18379349        0.50          Cytoplasmic vesicle membrane           Neurotransmitter transport
  6      Coronin, actin-binding protein, 1A                         gi∣5902134         2.00          Cytoplasm                              Component of the cytoskeleton of highly motile cells
  7      Fatty acid-binding protein 4                               gi∣4557579 (+1)    0.23          Cytoplasm, nucleus                     Lipid transport protein
  8      Peroxiredoxin 5                                            gi∣15826629        0.37          Mitochondrion, cytoplasm, peroxisome   Antioxidant, oxidoreductase peroxidase
  9      Heat shock 70 kDa protein 9                                gi∣24234688        0.15          Mitochondrion                          Control of cell proliferation and cellular aging
  10     Leucine aminopeptidase 3                                   gi∣41393561        2.94          Cell membrane, secreted                Cell-cell signaling
  11     Apolipoprotein D                                           gi∣619383          2.90          Secreted                               Lipid metabolic process
  12     L-plastin                                                  gi∣4504965         3.14          Cytoplasm, cell membrane               Activation of T cells, intracellular protein transport
  13     Anterior gradient protein 2 homolog precursor              gi∣5453541         0.11          Secreted, endoplasmic reticulum        Mucus secretion
  14     Heat shock 10 kDa protein 1                                gi∣4504523         0.37          Mitochondrion                          Stress response
  15     ATP synthase, H+ transporting, mitochondrial F1 complex    gi∣4757810         0.41          Mitochondrion                          Proton-transporting ATP synthase complex assembly
  16     Glutathione transferase                                    gi∣20664358 (+5)   3.29          Cytoplasm                              Glutathione metabolic process
  17     Chaperonin                                                 gi∣31542947        0.33          Mitochondrion                          Stress response
  18     Complement component 3 precursor                           gi∣115298678       3.00          Secreted                               Activation of the complement system
  19     Heterogeneous nuclear ribonucleoprotein D isoform a        gi∣14110420        2.19          Nucleus, cytoplasm                     Transcription regulation
  20     Malate dehydrogenase                                       gi∣6648067 (+1)    0.22          Cytoplasm                              Tricarboxylic acid cycle

###### 

Top 30 proteins predicting tumor response to neoadjuvant chemotherapy in TNBC tumors.

  Rank   Protein name                                                             Accession no.       R/IR + NR mean   Subcellular location                            Function
  ------ ------------------------------------------------------------------------ ------------------- ---------------- ----------------------------------------------- -----------------------------------------------------------------------
  1      Heat shock 70 kDa protein 8 isoform 1                                    gi∣5729877          0.32                                                             Stress response
  2      Periostin precursor (PN) (osteoblast-specific factor 2)                  gi∣93138709         0.31             Nucleus                                         Transcription regulation
  3      Cyclophilin A                                                            gi∣1633054          0.41             Secreted                                        Cell attachment adhesion and spreading
  4      Tyrosine 3/tryptophan 5-monooxygenase activation protein                 gi∣5803225 (+1)     3.71             Nucleus                                         Protein binding
  5      Profilin                                                                 gi∣157838211 (+4)   0.32             Cytoplasm, cytoskeleton                         Actin cytoskeleton organization
  6      Cardiac muscle alpha actin 1 proprotein                                  gi∣4885049          0.08             Cytoplasm, cytokeleton                          actin filament-based movement, apoptosis
  7      Beta actin                                                               gi∣4501885          0.22             Cytoplasm, cytokeleton                          Cell motility
  8      Caldesmon (CDM)                                                          gi∣2498204          0.42             Cytoplasm, cytokeleton                          Actin- and myosin-binding protein
  9      Tubulin *β*5                                                             gi∣7106439          0.19             Cytosol                                         Major constituent of microtubules
  10     Tropomyosin 2 (beta) isoform 1                                           gi∣42476296         0.11             Cytoplasm, cytokeleton                          Binding to actin filaments
  11     Actinin, *α*4                                                            gi∣12025678         0.11             Nucleus, cytoplasm                              Protein transport
  12     Ras homolog gene family, member A (RhoA)                                 gi∣10835049 (+4)    0.33             Cytoplasm, cell membrane                        Regulating a signal transduction pathway
  13     Heterogeneous nuclear ribonucleoprotein K                                gi∣13384620         0.33             Cytoplasm, nucleus                              Pre-mRNA-binding proteins
  14     Tubulin *α*1                                                             gi∣6755901          0.36             Cytosol                                         Major constituent of microtubules
  15     Tropomyosin 4                                                            gi∣4507651          0.35             Cytoplasm, cytokeleton                          Binds to actin filaments
  16     Complement component 1 inhibitor precursor                               gi∣73858568         4.57             Secreted                                        Complement pathway
  17     ATP synthase, H+ transporting, mitochondrial F1 complex                  gi∣4757810          0.43             Mitochondrion                                   Proton-transporting ATP synthase complex assembly
  18     Calnexin precursor                                                       gi∣10716563         0.42             Endoplasmic reticulum membrane, cell membrane   Calcium-binding protein
  19     Eukaryotic translation elongation factor 1 alpha 1                       gi∣4503471          0.29             Cytoplasm                                       Protein biosynthesis
  20     Annexin I                                                                gi∣4502101          0.25             Nucleus, cytoplasm, membrane                    Calcium/phospholipid-binding protein
  21     Triosephosphate isomerase 1                                              gi∣4507645 (+2)     0.35             Cytosol, nucleus                                Fatty acid biosynthesis, gluconeogenesis, glycolysis, lipid synthesis
  22     Cathepsin D preproprotein                                                gi∣4503143          0.35             Lysosome                                        proteolysis
  23     Alpha glucosidase II alpha subunit isoform 2                             gi∣38202257         0.19             Cytosol                                         Glycan metabolism, N-glycan metabolism
  24     Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein   gi∣4507949 (+1)     0.42             Nucleus                                         Protein binding
  25     Thymosin *β*10                                                           gi∣10863895         0.42             Cytoplasm, cytokeleton                          cytoskeleton organization
  26     Aconitase 2 precursor                                                    gi∣4501867          0.44             Mitochondrion                                   Carbohydrate metabolism, tricarboxylic acid cycle
  27     Heterogeneous nuclear ribonucleoprotein D isoform a                      gi∣14110420         0.48             Nucleus, cytoplasm                              Transcription regulation
  28     Serine (or cysteine) proteinase inhibitor                                gi∣32454741         0.25             Secreted                                        Inhibits activated protein C, plasminogen activator
  29     Lumican precursor                                                        gi∣4505047          0.28             Secreted                                        Binds to laminin
  30     Apolipoprotein D                                                         gi∣619383           2.86             Secreted                                        Transport
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